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In 2009, the development of a medical brief, effectively detailing the 
specifications for a purpose-built oncology hospital and including the 
medical equipment and human resources required, was commenced. 
Robust engagement by the relevant stakeholders, many of which 
hailed from the extant Sir Paul Boffa Hospital, ensured a very relevant 
proposal. The project (ERDF 196), led by the Foundation for Medical 
Sciences, was subsequently approved for partial funding through 
European Regional Development Funds. The new Sir Anthony Mamo 
Oncology Centre, as it came to be named, first opened its doors for 
service in December 2014 when the Out-patients Department received 
the first oncology patients. In April 2015, this was extended to include 
haematology and paediatric oncology patients. Full migration of 
services, including in-patient care, took place in September 2015.
The distribution of services within the new Centre includes five 
clinical areas for in-patients made up of two oncology wards, one 
radioisotope unit, one haematology ward and one palliative care ward, 
with a total of 88 beds, an out-patient unit with 12 clinic rooms, a day 
area for day-treatment with a total of 21 couches and eight beds, a 
clinical support services unit and a radiotherapy department.
The staff complement, a significant number of which are Health 
Sciences graduates, is very diverse. Specific training related to the care 
of cancer patients is currently ongoing and opportunities for continued 
professional development for all staff are being prioritised.
Special mention must be made of the dual-qualified radiographers 
who graduated through a course run jointly between the University 
of Malta and the University of Cardiff who were deployed within the 
Centre’s radiotherapy unit, and the medical physicists in radiotherapy, 
whose training, partially funded through ESF 4.175, occurred under the 
joint auspices of the University of Malta and Leeds Teaching Hospitals 
NHS Trust.
The very scope behind this large project is to ensure that the level of 
cancer patient management in Malta continues to improve, if possible 
on a par with that of countries with similar health systems. Recently 
published research has shown Malta to be somewhat middle-ranked on 
overall survivorship, demonstrating an age and case-mix standardised 
five-year relative survival of 51.3% for all cancers, only just below the 
average quoted for Europe (52.5%) (Baili et al., 2015).
To this effect, a number of developments are planned within the 
radiotherapy unit that will result in a decrease in patient treatment 
complications, and will allow for the treatment of individuals who 
hitherto were sent abroad, thus providing for a better patient experience. 
Within the next three years, plans are in place to develop Intensity-
Modulated Radiation Therapy (IMRT) and Volumetric Modulated 
Arc Therapy (VMAT), optimising treatment of relevant cancer sites 
through the provision of high dose conformance to the tumour, thereby 
reducing risk to critical structures. A reduction in treatment time, 
which potentially decreases the likelihood of patient movement during 
the therapy, will increase accuracy which, together with on-board on-
line imaging, will significantly enhance treatment precision.
Though in the past, a few Maltese patients were enrolled in clinical 
trials, plans for a significant drive to put this process on a more formal 
and universal footing through the set-up of a clinical trials unit within 
the Centre, are being addressed. The aim is to significantly improve 
access for Maltese patients to drugs-in-development and to allow 
for more significant participation in leading edge clinical trials. In 
conjunction with this, a well-resourced framework needs to be set up to 
facilitate the timely adoption of new pharmaceuticals, including the use 
of immunological therapies, especially in the context of personalised 
cancer management.
The local performance of autologous bone marrow transplants in the 
long term is also being given due consideration. However, this depends 
heavily on further staff training, recruitment of additional expertise, 
and on other infrastructural projects, mainly the Innovation Centre for 
Excellence – Blood, Tissues and Cells (ICE-BTC), approval of which is 
currently pending a specific ERDF call for applications.
In order to truly ascertain that the patient is at the very core of this 
enterprise, the Sir Anthony Mamo Oncology Centre should attempt to 
achieve accreditation. Similar hospitals in Europe have undergone this 
laborious yet very constructive quality measure and have been certified 
by institutions such as Joint Commission International. This will 
undoubtedly have a profound impact on the operational performance 
of the hospital, ensuring that all processes within the hospital are 
optimally geared towards the patient.
Of course, the Sir Anthony Mamo Oncology Centre will not be 
operating in a vacuum. Significant co-operative ventures are ongoing, 
whereby expertise is being transferred and co-operation is being sought. 
A bilateral arrangement with Leeds Teaching Hospitals NHS Trust has 
contributed significantly to the developments in radiotherapy, both in 
terms of equipment validation and of planned evolution in treatment 
methodology. Malta is also actively participating in the European 
Reference Networks project, an EU Commission initiative whereby 
highly specialised healthcare providers are designated as centres 
of expertise or reference. This in turn enables the concentration of 
expertise and patient numbers in one place to optimally manage rare 
or complex diseases including many cancers. On a more local level, 
the existing synergies with Mater Dei Hospital should be strengthened 
and new ones built with the University of Malta and possibly the 
Life Sciences Centre, exploiting the adjacency of these institutions. 
There should also be additional focus on strengthening the existing 
relationships with non-governmental organisations since these all bring 
a particular ethos of their own that touches patients in different ways.
All this should be complemented by a continued transfer of care from 
an in-patient/hospital environment to a community-based one that 
will allow patients to enjoy the comforts of their personal surroundings 
and families for a larger part of their treatment. Stronger co-operation 
with community-based care providers is extremely important, as is 
the investment in robust information systems that would effectively 
underlie all the highlighted developments.
The Sir Anthony Mamo Oncology Centre will therefore, in the coming 
years, effectively serve as the backdrop for significant advancements 
which will hopefully alter for the better the outcome of the battle 
against cancer.
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